Gaines v. AstraZeneca Pharmaceutical

CourtDistrict Court, S.D. New York
DecidedSeptember 7, 2023
Docket1:21-cv-05323
StatusUnknown

This text of Gaines v. AstraZeneca Pharmaceutical (Gaines v. AstraZeneca Pharmaceutical) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Gaines v. AstraZeneca Pharmaceutical, (S.D.N.Y. 2023).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ERNEST EDWARD GAINES, Plaintiff, 21-CV-5323 (LTS) -against- ORDER ASTRAZENECA PHARMACEUTICAL, et al., Defendants. LAURA TAYLOR SWAIN, United States District Judge: Plaintiff filed this action pro se. By order dated September 26, 2022, the Court dismissed the amended complaint for lack of subject matter jurisdiction. Now before the Court are two motions in this closed action: a motion under Rule 60(b) of the Federal Rules of Civil Procedure (ECF 49), and a motion for a stay and other relief (ECF 50). BACKGROUND Plaintiff is incarcerated in Texas, and he indicates that he currently suffers from diabetes. In his initial complaint, Plaintiff asserted (1) claims against Astrazeneca Pharmaceutical, LP (Astrazeneca), which sells the medication Seroquel, and (2) claims against Texas law firms for their handling of a 2009 New York state-court class action suit against Astrazeneca, in which Plaintiff was a class member. See Fishman et al. v. Astrazeneca Pharmaceuticals, LP, et al., Index No. 09109049 (N.Y. Sup. Ct.). Plaintiff alleged that from December 21, 2005, to June 12, 2006, while at the Dallas County Jail in Texas, he was prescribed Seroquel for his schizophrenia and bi-polar disorder. (ECF 2 at 22.) At the time of the class action settlement in 2012, Plaintiff had not been diagnosed with diabetes, and his net award— after paying $4,485.98 in attorney’s fees and $392.26 in costs— was $6,336.71. (Id. at 35.) In May 2014, while still incarcerated in Texas and approximately eight years after his 6- month course of treatment with Seroquel, Plaintiff was diagnosed with diabetes. Plaintiff now asserts in the amended complaint that the settlement that he received from Astrazeneca is not enough.1 Plaintiff states that he read in a Bloomberg News article, which was published in

February 2011, that the average payout for settlement of claims that Seroquel caused diabetes was $25,000. Plaintiff asserted that the attorneys “shortage[d] [him] on the settlement by $14,000.” (Id. at 15.) In his original complaint, Plaintiff neither asserted a federal claim nor pleaded facts establishing diversity jurisdiction, under 28 U.S.C. § 1332. The Court granted Plaintiff several opportunities to allege facts showing that the Court has subject matter jurisdiction of this action; notified him that he could drop any nondiverse defendants in order to establish diversity jurisdiction; and granted him repeated extensions of time to do so. (ECF Nos. 8, 11, 13, 18, 20.) The Court dismissed the action when Plaintiff failed to file an amended complaint within the extended deadline (ECF 21, 22), but then vacated the order of dismissal (ECF 31) after Plaintiff eventually filed an amended complaint (ECF 23).2 Once the action was reopened, the Court

reviewed the amended complaint and, by order dated September 26, 2022, dismissed it for lack of subject matter jurisdiction, on the ground that Plaintiff had failed to plead facts establishing either federal question or diversity jurisdiction.

1 The Court has previously suggested that Plaintiff contact the settlement administrator for the state court action. Plaintiff had attempted to file documents in the state court action, but because he labeled the documents for the “United States Supreme Court,” the state court misunderstood that the papers were intended for the federal court. 2 After the Court vacated the order of dismissal, the Court of Appeals dismissed Plaintiff’s appeal from an earlier order of this Court. (ECF 47.) Plaintiff states that on October 17, 2022, after this action was closed, he mailed to the Court a “motion for panel rehearing / rehearing en banc,” which he intended as a challenge to the order of dismissal.3 That application does not appear on the Court’s docket. On November 21, 2022, the Court received a letter from Plaintiff noting that he had not received a certified mail

receipt for his October 17, 2022 motion. Plaintiff now brings a motion, under Rule 60(b), which challenges the September 26, 2022 order of dismissal, and he incorporates his “motion for panel rehearing / rehearing en banc.” (ECF 49.) Plaintiff also brings a motion (ECF 50), which is styled as (1) a request for leave to file a motion to stay, though this action is closed, and it is therefore unclear what actions Plaintiff seeks to stay; and (2) a request for an extension of time under Rule 30 of the Rules of the Supreme Court of the United States, in connection with an application to the Supreme Court of the State of New York.4 DISCUSSION Under Rule 60(b), a party may seek relief from a district court’s order or judgment for the following reasons:

(1) mistake, inadvertence, surprise, or excusable neglect; (2) newly discovered evidence that, with reasonable diligence, could not have been discovered in time to move for a new trial under Rule 59(b); (3) fraud (whether previously called intrinsic or extrinsic), misrepresentation, or other misconduct of an opposing party; (4) the judgment is void; (5) the judgment has been satisfied, released, or discharged; it is based on an earlier judgment that has been reversed or vacated; or

3 Plaintiff also attaches the cover letter that he sent with the “motion for panel rehearing / rehearing en banc.” Because Plaintiff references the Federal Rules of Appellate Procedure, and he had another “motion for panel rehearing / rehearing en banc” pending in the Court of Appeals for the Second Circuit, there may have been some confusion about whether his application was intended for the district or circuit court. 4 The United States Supreme Court is the highest federal court. The Supreme Court of the State of New York is the trial court (or lower level court) for the State of New York. applying it prospectively is no longer equitable; or (6) any other reason justifying relief. Fed. R. Civ. P. 60(b). A motion based on reasons (1), (2), or (3) must be filed “no more than one year after the entry of the judgment or order or the date of the proceeding.” Fed. R. Civ. P. 60(c)(1). The Court understands Plaintiff’s motion to seek leave to reopen this action and file an amended complaint that drops the two law firms named as defendants: Ferrer, Poirot & Wansbrough, and “Howard L. Nations, The Nations Law Firm.”5 This would leave AstraZeneca as the sole defendant and, although Plaintiff’s motion does not provide facts showing diversity jurisdiction, diversity of citizenship may exist between Plaintiff and AstraZeneca. The Court

concludes that Plaintiff shows excusable neglect, under Rule 60(b)(1), and therefore grants Plaintiff’s motion for reconsideration of the order of dismissal, reopens this action, and directs Plaintiff to file a second amended complaint that drops the non-diverse defendants and names Astrazeneca as the sole defendant. In his second amended complaint, Plaintiff may wish to address: (1) the timeliness of his claims against Astrazeneca (given that he apparently took Seroquel in 2005-2006, discovered his diabetes in 2014, and commenced this action (with adjustment for the “prison mailbox rule”) on April 2, 2020), and whether there is any basis for tolling of the limitations period;6 (2) whether

5 It was unclear if Plaintiff had intended to sue the individual attorney, Howard Nations, or his law firm.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Coppedge v. United States
369 U.S. 438 (Supreme Court, 1962)
Gerena v. Korb
617 F.3d 197 (Second Circuit, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
Gaines v. AstraZeneca Pharmaceutical, Counsel Stack Legal Research, https://law.counselstack.com/opinion/gaines-v-astrazeneca-pharmaceutical-nysd-2023.